Vaccine effect of granulocyte-macrophage colony-stimulating factor or CD80 gene-transduced murine hematopoietic tumor cells and their cooperative enhancement of antitumor immunity

Gene Therapy

Volumn 5, Issue 10, 1998, Pages 1355-1362

  Nakazaki, Y ^a   Tani, K ^a   Lin, Z T ^a   Sumimoto, H ^a   Hibino, H ^a   Tanabe, T ^a   Wu, M S ^a   Izawa, K ^a   Hase, H ^a   Takahashi, S ^a   Tojo, A ^a   Azuma, M ^b   Hamada, H ^c   Mori, S ^a   Asano, S ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c CANCER INSTITUTE   (Japan)

Author keywords

CD80; GM CSF; Immunogene therapy; Leukemia lymphoma; Tumor vaccine

Indexed keywords

B7 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; MOUSE; MYELOMONOCYTIC LEUKEMIA; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; T LYMPHOCYTE; THYMUS LYMPHOMA; TUMOR IMMUNITY; VACCINATION;

EID: 7844245078     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300726     Document Type: Article

References (35)

1. Coleman S et al. Autologous MHC-dependent leukaemia-reactive T lymphocytes in a patient with chronic myeloid leukaemia. Leukemia 1996; 10: 483-487.
2. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
3. Tepper RI, Mulé JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
4. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
5. Morita T et al. Tumor vaccination with macrophage colony-stimulating factor-producing Lewis lung carcinoma in mice. Blood 1996; 88: 955-961.
6. Hellstrom KE, Hellström I, Chen L. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev 1995; 145: 123-145.
7. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-258.
8. Penninger JM et al. Spontaneous resistance to acute T cell leukaemias in TCRVγ1.1Jγ4Cγ4 transgenic mice. Nature 1995; 375: 241-244.
9. Tazi A et al. Evidence that granulocyte-macrophage colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers. J Clin Invest 1993; 91: 566-576.
10. Lu L et al. Generation of DC from mouse spleen cell cultures in response to GM-CSF: immunophenotypic and functional analyses. Immunology 1995; 84: 127-134.
11. Sallusto F, Cella M, Danieli C, Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995; 182: 389-400.
12. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte-macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J Exp Med 1994; 179: 1109-1118.
13. Larsen CP et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1, B7-2) expression on murine dendritic cells. J Immunol 1994; 152: 5208-5219.
14. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting antitumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
15. Sanda MG et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol 1994; 151: 622-628.
16. Levitsky HI et al. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996; 156: 3858-3865.
17. Chen L et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
18. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
19. Chen L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
20. Townsend SE, Su FW, Atherton JM, Allison JP. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors. Cancer Res 1994; 54: 6477-6483.
21. Wu TC et al. A reassessment of the role of B7-1 expression in tumor rejection. J Exp Med 1995; 182: 1415-1421.
22. Chen L et al. B7-1/CD80-transduced tumor cells elicit better systemic immunity than wild-type tumor cells admixed with Corynebacterium parvum. Cancer Res 1994; 54: 5420-5423.
23. + T lymphocytes in the P815 tumor system in vitro. J Immunol 1996; 156: 465-472.
24. Matulonis UA et al. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995; 85: 2507-2515.
25. Dunussi-Joannopoulos K et al. Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 1996; 87: 2938-2946.
26. Cayeux S et al. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines. Eur J Immunol 1995; 25: 2325-2331.
27. Cayeux S, Beck C, Dörken B, Blankenstein T. Coexpression of interleukin-4 and B7.1 in murine tumor cells leads to improved tumor rejection and vaccine effect compared to single gene transfectants and a classical adjuvant. Hum Gene Ther 1996; 7: 525-529.
28. Salvadori S et al. B7-1 amplifies the response to interleukin-2-secreting tumor vaccines in vivo, but fails to induce a response by naive cells in vitro. Hum Gene Ther 1995; 6: 1299-1306.
29. Zitvogel L et al. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996; 26: 1335-1341.
30. Chambers BJ, Salcedo M, Ljunggren H-G. Triggering of natural killer cells by the costimulatory molecule CD80 (B7-1). Immunity 1996; 5: 311-317.
31. Simons JW et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997; 57: 1537-1546.
32. Ellem KA et al. A case report: immune responses and clinical course of the first human use of granulocyte-macrophage colony-stimulating factor transduced autologous melanoma cells for immunotherapy. Cancer Immunol Immunother 1997; 44: 10-20.
33. Murphy WH, Urnovitz HB, Maryanski JL, Abrams GD. Characterization of transplantable myelomonocytic leukemia WEHI-3B in syngeneic BALB/c mice. Proc Soc Exp Biol Med 1978; 157: 556-564.
34. Wein J, Roberts E. Influence of H-2 isoantibody on electrophoretic behavior of EL4 lymphoma cells. Cancer Res 1965; 25: 1753-1758.
35. Wakimoto H et al. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 1996; 56: 1828-1833.